RFG Advisory LLC Boosts Position in Johnson & Johnson (NYSE:JNJ)

RFG Advisory LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 7.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,494 shares of the company’s stock after buying an additional 1,336 shares during the quarter. RFG Advisory LLC’s holdings in Johnson & Johnson were worth $2,703,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Grimes & Company Inc. grew its stake in shares of Johnson & Johnson by 2.7% in the fourth quarter. Grimes & Company Inc. now owns 95,715 shares of the company’s stock worth $15,002,000 after acquiring an additional 2,544 shares during the last quarter. Stratos Investment Management LLC lifted its holdings in Johnson & Johnson by 4.3% in the fourth quarter. Stratos Investment Management LLC now owns 27,239 shares of the company’s stock valued at $4,269,000 after acquiring an additional 1,132 shares during the period. Stratos Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 1.6% in the fourth quarter. Stratos Wealth Advisors LLC now owns 35,776 shares of the company’s stock worth $5,608,000 after buying an additional 553 shares during the period. Tritonpoint Wealth LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $13,984,000. Finally, DekaBank Deutsche Girozentrale grew its holdings in Johnson & Johnson by 4.8% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 4,396,416 shares of the company’s stock valued at $688,198,000 after buying an additional 200,193 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JNJ. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. TD Securities decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Morgan Stanley increased their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Trading Down 0.7 %

Shares of Johnson & Johnson stock traded down $1.11 during trading on Monday, reaching $159.51. 5,072,474 shares of the company were exchanged, compared to its average volume of 7,339,593. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.60. The business has a 50-day moving average price of $151.17 and a 200-day moving average price of $153.06. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $383.89 billion, a price-to-earnings ratio of 9.94, a P/E/G ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period last year, the company posted $2.80 EPS. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. Sell-side analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.11%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.